You are here

Article info

Article menu

Download PDFPDF

XML
Cancer genetics
Short report
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

Authors

  • Hildur Helgadottir Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Paola Ghiorzo Department of Internal Medicine and Medical Specialties, University of Genoa and Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy PubMed articlesGoogle scholar articles
  • Remco van Doorn Department of Dermatology, LUMC, Leiden, The Netherlands PubMed articlesGoogle scholar articles
  • Susana Puig Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Max Levin Department of Oncology, The Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden PubMed articlesGoogle scholar articles
  • Richard Kefford Department of Clinical Medicine, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Martin Lauss Department of Oncology, Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden. PubMed articlesGoogle scholar articles
  • Paola Queirolo Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy PubMed articlesGoogle scholar articles
  • Lorenza Pastorino Department of Internal Medicine and Medical Specialties, University of Genoa and Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy PubMed articlesGoogle scholar articles
  • Ellen Kapiteijn Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands PubMed articlesGoogle scholar articles
  • Miriam Potrony Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Cristina Carrera Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Håkan Olsson Department of Oncology, Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden. PubMed articlesGoogle scholar articles
  • Veronica Höiom Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Göran Jönsson Department of Oncology, Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden. PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Hildur Helgadottir, Department of Oncology and Pathology, Karolinska Institutet and Karolinska University Hospital, Solna 171 76, Stockholm; Hildur.Helgadottir{at}karolinska.se
View Full Text

Citation

Helgadottir H, Ghiorzo P, van Doorn R, et al
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
Journal of Medical Genetics 2020;57:316-321.

Publication history

  • Received July 18, 2018
  • Revised August 23, 2018
  • Accepted September 11, 2018
  • First published October 5, 2018.
Online issue publication 
April 23, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.